Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $782,880.00 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $111.84, for a total transaction of $782,880.00. Following the sale, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $3,659,181.12. The trade was a 17.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Monday, June 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.28, for a total value of $550,568.16.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics stock opened at $109.69 on Thursday. The stock has a market cap of $7.26 billion, a P/E ratio of -54.03 and a beta of -0.34. The stock’s fifty day moving average is $90.33 and its 200 day moving average is $64.44. Oruka Therapeutics, Inc. has a one year low of $14.10 and a one year high of $115.52.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Analysts predict that Oruka Therapeutics, Inc. will post -2.27 EPS for the current year.

Institutional Trading of Oruka Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new position in shares of Oruka Therapeutics during the first quarter valued at about $2,505,000. JPMorgan Chase & Co. boosted its stake in Oruka Therapeutics by 567.7% during the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after buying an additional 13,115 shares during the last quarter. Legal & General Group Plc purchased a new position in Oruka Therapeutics during the 2nd quarter valued at approximately $28,000. Rhumbline Advisers purchased a new position in Oruka Therapeutics during the 2nd quarter valued at approximately $320,000. Finally, New York State Common Retirement Fund bought a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $96,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ORKA shares. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. UBS Group raised their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Piper Sandler restated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Guggenheim reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, Wedbush reiterated an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.